Access to this content is restricted
Learning objectives
- To understand the best standard approach for patients with localised oesophageal cancer
- To select the optimal sequence of Immune Checkpoint Inhibitors when treating advanced oesophageal cancer
- To properly use different predictive biomarkers to get the maximum benefit of Immune Checkpoint Inhibitors